MCC
BCRX icon

Money Concepts Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Money Concepts Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-178
Closed -$2.04K – 686
2022
Q4 		$2.04K Buy
+178
New +$2.22K ﹤0.01% 2678

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Money Concepts Capital's BCRX Position: Q1 2023 in Review

Money Concepts Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 178 shares — an estimated $2.04K sold.

Money Concepts Capital first reported a position in BCRX in Q4 2022 and held it in 1 quarter. The position peaked at $2.04K in Q4 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Money Concepts Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 178 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $2.04K.
  • Money Concepts Capital first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's BioCryst Pharmaceuticals position peaked at $2.04K in Q4 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.